West Pharmaceutical Services revenue and financials

WST · NYSE · USD

$372.64−1.09%−$4.12

Close · October 6, 2026

In the fiscal year ended December 2025, West Pharmaceutical Services reported revenue of $3.07B (+6.25% year over year). Net income was $493.7M, a net margin of 16.1%.

Annual revenue · 2025: $3.07B
  1. $1.51B2016
  2. $1.6B2017
  3. $1.72B2018
  4. $1.84B2019
  5. $2.15B2020
  6. $2.83B2021
  7. $2.89B2022
  8. $2.95B2023
  9. $2.89B2024
  10. $3.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+6.25%
2025 vs 2024
Net income growth
+0.20%
2025 vs 2024
Net margin
16.1%
2024: 17.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets4,0764,1104,2704,1063,9533,6183,6433,6753,4893,6023,8303,755
Current assets1,8081,8271,9781,8231,6811,4581,5381,5511,4831,6931,9361,972
Cash and equivalents436521791629510404485491446602854899
Receivables729701586653610569576567502544534539
Inventory447453444438421389377401419430435432
Net property, plant and equipment1,8241,8461,8781,8741,8611,7671,7161,7111,6351,5451,5131,408
Goodwill109109110111111108106109107108109107
Other intangible assets6.47.07.78.99.710.010.812.312.913.915.115.7
Long-term investments208209212221225212202218198203210195
Current liabilities641674655635605527550517634648672534
Accounts payable253252254256239228239224212240242220
Long-term debt20320320320320320320320372.972.872.8152
Total debt312316321298303———————
Total liabilities1,0861,1191,0941,0541,024935961923913922949887
Total equity (incl. minority)2,9902,9903,1763,0522,9292,6832,6822,7522,5772,6812,8812,868
Retained earnings4,6244,4764,3754,2624,1394,0313,9573,8573,7213,6243,5233,416